The company is expanding its cardiology portfolio with a new treatment for transthyretin amyloid cardiomyopathy in Europe.

Bayer’s head of Pharmaceuticals talks to Euractiv about US tariffs, expresses scepticism over CMA, and how the discussion on RDP should be focused on increasing it for incentivising competitiveness.

Bayer said on Tuesday it was preparing market launches this year of two new drugs that could each have annual peak sales of at least $1 billion, as it seeks to strengthen its pharmaceuticals business ...

Bayer's AI Innovation Platform (AIIP), powered by Google Cloud technology, streamlines the development of AI-driven medical ...

Antihemophilic Factor binds factor IXa along with calcium and phospholipid. This complex converts factor X to factor Xa to ...

Bayer says it disagrees with the verdict and plans to appeal. But the German pharmaceutical and biotechnology group faces ...

European healthcare stocks tumble as Trump prepares new tariffs, with pharmaceutical firms bracing for economic fallout and market uncertainty.